Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
Plantar Fibromatosis|Ledderhose Disease
BIOLOGICAL: EN3835|OTHER: Placebo
Change from Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hour) Pain (ADP) Score as Measured on the Pain Intensity Numeric Rating Scale (NRS), Baseline, Week 12
Change from Baseline in the Foot Function Index (FFI) Difficulty Subscale Score, Baseline, up to Day 85|Change from Baseline in the FFI Activity Limitation Subscale Score, Baseline, up to Day 85|Change from Baseline in the FFI Pain Subscale Score, Baseline, up to Day 85|Change from Baseline in the FFI Total Score, Baseline, up to Day 85|Number of Participants That Used Rescue Analgesic Medication, Up to Day 85|Amount of (milligrams [mg]) Rescue Analgesic Medication Used, Up to Day 85|Patient Global Impression of Change (PGIC) Foot Pain Score, Up to Day 85|Clinician Global Impression of Change (CGIC) Score, Up to Day 85|Subject Satisfaction Score, Up to Day 85|Change from Baseline in Nodule Consistency (Firmness), Baseline, up to Day 85|Change from Baseline in the Nodular Hardness of the Treated Nodules, Up to Day 85
This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).